Featuring an address from Pamela Fralick, President of Innovative Medicines Canada And a lively Life Sciences Panel Discussion
EDMONTON, Nov. 26, 2017 /CNW/ - What is the contribution of the innovative pharmaceutical industry to the Canadian economy and R&D investment? What are the potential impacts of federal policy changes aimed at lowering drug prices? Is there a middle ground where Canada is able to lower prices while still retaining its position as a top tier destination for clinical trials and the launch of new innovative medicines?
Pamela Fralick and the panelists will take a robust look at the results of a Fall 2017 analysis by EY about industry's contributions to Canada and how industry and government can work together to enhance affordable, equitable and timely access to new therapies.
Innovative Medicines Canada President Pamela Fralick will be available for media interviews after the event.
Mel Wong, President, BioAlberta (Emcee)
Pamela C. Fralick: President – Innovative Medicines Canada
Karen Wichuk, Executive Lead, Health City
Dr. Bob Turner, Member of Legislative Assembly - NDP (hematologist and oncologist)
Justin Riemer, ADM, Alberta Health, Innovation and External Relations
Monday, November 27, 2017
11:30 AM - 1:30 PM
The Westin Edmonton
10135 - 100th Street
Edmonton, AB T5J 0N7
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada's innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members' commitment to being valued partners in the Canadian healthcare system.
SOURCE Innovative Medicines Canada
For further information: Media: Anne Babineau, Director, Prairies, (403) 984-3244; Or Sarah Dion-Marquis, Director, Media and Public Relations, (613) 769-6510